Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer
Clinical trial NCT05659056 · UNKNOWN
Trial details
- NCT number
- NCT05659056
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-11-29
- Primary completion
- 2024-04-01
- Enrollment
- 65
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.